Description

Technical Parameters

Introduction

peptides

product-1400-1400

Products Description

### Systematic introduction: Classification, characteristics and clinical application of Gonadorelin peptides

Gonadorelin (gonadotropin-releasing hormone, GnRH) is a decapeptide hormone secreted by the hypothalamus, which regulates reproductive function by regulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Natural GnRH and its synthetic analogs (agonists and antagonists) are widely used in clinical practice in reproductive medicine, tumor treatment and other fields. This article systematically classifies and analyzes Gonadorelin peptides from the perspectives of structure, physicochemical properties, color and clinical application.

### 1. Natural GnRH (Gonadorelin)

**Structural characteristics**

- **Amino acid sequence**: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (10 peptides).

- **Molecular weight**: about 1182.3 Da.

**Physical and chemical properties**

- **Solubility**: Soluble in water or dilute acetic acid, with optimal stability at pH 4-6.

- **Stability**: Plasma half-life is only 2-4 minutes, easily degraded by endopeptidases.

- **Storage conditions**: Need to be freeze-dried and stored (-20℃), avoid repeated freezing and thawing.

**Color and morphology**

- The pure product is a white to off-white powder, and the solution is colorless and transparent.

**Advantages and limitations**

- **Advantages**: Clear biological activity, no artificial modification side effects.

- **Disadvantages**: Short half-life, continuous pulse administration is required, and clinical application is limited.

**Application**

- Diagnosis: Evaluation of pituitary function (such as GnRH stimulation test).

### 2. Synthetic GnRH analogs

Synthetic analogs extend the half-life or change the receptor action through structural modification, and are divided into two categories: **agonists** and **antagonists**.

#### (I) GnRH agonist analogs

**Structural modification strategy**

- **Substitution at position 6**: Gly→hydrophobic D-amino acid (such as D-Leu, D-Trp).

- **Modification at position 10**: Gly-NH₂→ethylamide (-NH-CH₂-CH₃), enhancing enzyme resistance.

**Representative drugs and characteristics**

1. **Leuprolide**

- **Sequence**: pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt.

- **Molecular weight**: 1209.4 Da (acetate).

- **Solubility**: Highly water-soluble (prepared in acetate buffer).

- **Half-life**: 3-4 hours (long-acting microsphere preparations can reach several months).

- **Color**: White lyophilized powder, colorless solution.

- **Advantages**: Long-acting sustained release, used for prostate cancer and endometriosis.

2. **Goserelin**

- **Structure**: D-Ser(tBu) at position 6, Aza-Gly at position 10.

- **Dosage form**: Subcutaneous implant, sustained release for 28 days.

- **Stability**: Resistant to gastrointestinal enzymatic hydrolysis, need to be stored away from light.

**Common advantages**

- Initial "Flare-up effect" stimulates hormone secretion, followed by downregulation of receptors.

- Long-acting preparations reduce dosing frequency and improve compliance.

#### (II) GnRH antagonist analogs

**Structural features**

- Multiple substitution modifications (such as positions 1, 2, 3, 6, and 8) block receptor activation.

- Commonly used D-amino acids and aromatic groups for substitution.

**Representative drugs and properties**

1. **Cetrorelix**

- **Sequence**: Ac-D-Nal-D-Phe(pCl)-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH₂.

- **Molecular weight**: 1431.6 Da.

- **Solubility**: Mannitol is required for solubilization, stable at pH 5.5-6.5.

- **Half-life**: 15-20 hours, daily subcutaneous injection.

- **Color**: White crystalline powder, clear solution.

- **Advantages**: No flare-up effect, directly inhibits gonadotropin.

2. **Ganirelix**

- **Structure**: D-Arg at the 2nd position, D-Ala at the 3rd position.

- **Application**: Prevention of premature ovulation in assisted reproduction.

**Common advantages**

- Rapid onset of action, no risk of hormone fluctuations.

- Suitable for the prevention of ovarian hyperstimulation syndrome (OHSS).

### 3. Other classification dimensions

#### (1) By route of administration

- **Injections**: such as leuprorelin microspheres (intramuscular injection).

- **Nasal spray**: natural GnRH analogs (frequent administration required).

- **Implants**: goserelin (biodegradable material sustained release).

#### (2) By indication

- **Tumor treatment**: agonists are used for hormone-dependent cancers (such as breast cancer and prostate cancer).

- **Reproductive medicine**: antagonists are used for in vitro fertilization cycle regulation.

### 4. In-depth analysis of physical and chemical properties

1. **Factors affecting stability**

- **Temperature**: Most need to be stored at 2-8℃, and long-acting preparations can be stored at room temperature for a short period of time.

- **pH sensitivity**: easily hydrolyzed under alkaline conditions (such as ester bond cleavage).

2. **Color change tips**

- Yellowing or turbidity may indicate degradation (such as oxidation or polymerization) and should be discarded.

### 5. Future development direction

- **Oral delivery system**: Nanocarrier encapsulation improves bioavailability.

- **Multifunctional analogs**: Combination with targeted anti-tumor drugs (such as GnRH-chemotherapy conjugates).

### Conclusion

Gonadorelin peptides have expanded clinical application scenarios through structural optimization, and agonists and antagonists have their own advantages. In the future, with the advancement of delivery technology and molecular design, its potential in personalized medicine will be further released.